|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kaufmann M, Hortobagyi GN, Goldhirsch A,
Scholl S, Makris A, Valagussa P, Blohmer JU, Eiermann W, Jackesz R,
Jonat W, et al: Recommendations from an international expert panel
on the use of neoadjuvant (primary) systemic treatment of operable
breast cancer: An update. J Clin Oncol. 24:1940–1949. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rastogi P, Anderson SJ, Bear HD, Geyer CE,
Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil
SR, et al: Preoperative chemotherapy: Updates of national surgical
adjuvant breast and bowel project protocols B-18 and B-27. J Clin
Oncol. 26:778–785. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Early Breast Cancer Trialists'
Collaborative Group (EBCTCG), . Long-term outcomes for neoadjuvant
versus adjuvant chemotherapy in early breast cancer: Meta-analysis
of individual patient data from ten randomised trials. Lancet
Oncol. 19:27–39. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
von Minckwitz G, Untch M, Blohmer JU,
Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich
J, Huober J, et al: Definition and impact of pathologic complete
response on prognosis after neoadjuvant chemotherapy in various
intrinsic breast cancer subtypes. J Clin Oncol. 30:1796–1804. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fayanju OM, Ren Y, Thomas SM, Greenup RA,
Plichta JK, Rosenberger LH, Tamirisa N, Force J, Boughey JC, Hyslop
T and Hwang ES: The clinical significance of breast-only and
node-only pathologic complete response (PCR) after neoadjuvant
chemotherapy (NACT): A review of 20,000 breast cancer patients in
the national cancer data base (NCDB). Ann Surg. 268:591–601. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Viale G: Characterization and clinical
impact of residual disease after neoadjuvant chemotherapy. Breast.
22 (Suppl 2):S88–S91. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cortazar P, Zhang L, Untch M, Mehta K,
Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L,
Valagussa P, et al: Pathological complete response and long-term
clinical benefit in breast cancer: The CTNeoBC pooled analysis.
Lancet. 384:164–172. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES,
Yokota I, Kuroi K, Im SA, Park BW, Kim SB, et al: Adjuvant
capecitabine for breast cancer after preoperative chemotherapy. N
Engl J Med. 376:2147–2159. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Von Minckwitz G, Huang CS, Mano MS, Loibl
S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A,
Redondo A, et al: Trastuzumab emtansine for residual invasive
HER2-positive breast cancer. N Engl J Med. 380:617–628. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Templeton AJ, McNamara MG, Šeruga B,
Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G,
Knox JJ, Tran B, et al: Prognostic role of neutrophil-to-lymphocyte
ratio in solid tumors: A systematic review and meta-analysis. J
Natl Cancer Inst. 106:dju1242014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Paramanathan A, Saxena A and Morris DL: A
systematic review and meta-analysis on the impact of pre-operative
neutrophil lymphocyte ratio on long term outcomes after curative
intent resection of solid tumours. Surg Oncol. 23:31–39. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Faria SS, Fernandes PC Jr, Silva MJ, Lima
VC, Fontes W, Freitas-Junior R, Eterovic AK and Forget P: The
neutrophil-to-lymphocyte ratio: A narrative review.
Ecancermedicalscience. 10:7022016.PubMed/NCBI
|
|
14
|
Qian Y, Tao J, Li X, Chen H, Lu Q, Yang J,
Pan H, Wang C, Zhou W and Liu X: Peripheral inflammation/immune
indicators of chemosensitivity and prognosis in breast cancer
patients treated with neoadjuvant chemotherapy. Onco Targets Ther.
11:1423–1432. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen Y, Chen K, Xiao X, Nie Y, Qu S, Gong
C, Su F and Song E: Pretreatment neutrophil-to-lymphocyte ratio is
correlated with response to neoadjuvant chemotherapy as an
independent prognostic indicator in breast cancer patients: A
retrospective study. BMC Cancer. 16:3202016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bae SJ, Cha YJ, Yoon C, Kim D, Lee J, Park
S, Cha C, Kim JY, Ahn SG, Park HS, et al: Prognostic value of
neutrophil-to-lymphocyte ratio in human epidermal growth factor
receptor 2-negative breast cancer patients who received neoadjuvant
chemotherapy. Sci Rep. 10:130782020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Asano Y, Kashiwagi S, Onoda N, Noda S,
Kawajiri H, Takashima T, Ohsawa M, Kitagawa S and Hirakawa K:
Predictive value of neutrophil/lymphocyte ratio for efficacy of
preoperative chemotherapy in triple-negative breast cancer. Ann
Surg Oncol. 23:1104–1110. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chae S, Kang KM, Kim HJ, Kang E, Park SY,
Kim JH, Kim SH, Kim SW and Kim EK: Neutrophil-lymphocyte ratio
predicts response to chemotherapy in triple-negative breast cancer.
Curr Oncol. 25:e113–e119. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rao JS, Hanumappa HK, Joseph EP, Chowdappa
RG and Ramesh R: Elevated neutrophil-lymphocyte ratio in
luminal-type locally advanced breast cancer to circumvent
neo-adjuvant chemotherapy. Indian J Surg Oncol. 10:454–459. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rivas M, Acevedo F, Dominguez F, Galindo
H, Camus M, Oddo D, Villarroel A, Razmilic D, Peña J, Munoz Medel
M, et al: The neutrophil to lymphocyte ratio predicts the response
to neoadjuvant chemotherapy in luminal B breast cancer. Asian Pac J
Cancer Prev. 20:2209–2212. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Coleman N, Rom FM, Brennan A, Bennett K,
Jayaram AK and Kennedy MJ: Does baseline absolute
neutrophil-to-lymphocyte ratio (Nlr) correlate with pathological
complete response (Pcr) in neoadjuvant breast cancer (Bc)? Ann
Oncol. 25 (Suppl 4):IV1132014. View Article : Google Scholar
|
|
22
|
Eryilmaz MK, Mutlu H, Salim DK, Musri FY,
Tural D and Coskun HS: The neutrophil to lymphocyte ratio has a
high negative predictive value for pathologic complete response in
locally advanced breast cancer patients receiving neoadjuvant
chemotherapy. Asian Pac J Cancer Prev. 15:7737–7740. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Koh YW, Lee HJ, Ahn JH, Lee JW and Gong G:
Prognostic significance of the ratio of absolute neutrophil to
lymphocyte counts for breast cancer patients with ER/PR-positivity
and HER2-negativity in neoadjuvant setting. Tumour Biol.
35:9823–9830. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Suppan C, Bjelic-Radisic V, La Garde M,
Groselj-Strele A, Eberhard K, Samonigg H, Loibner H, Dandachi N and
Balic M: Neutrophil/lymphocyte ratio has no predictive or
prognostic value in breast cancer patients undergoing preoperative
systemic therapy. BMC Cancer. 15:10272015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Graziano V, Grassadonia A, Iezzi L, Vici
P, Pizzuti L, Barba M, Quinzii A, Camplese A, Di Marino P, Peri M,
et al: Combination of peripheral neutrophil-to-lymphocyte ratio and
platelet-to-lymphocyte ratio is predictive of pathological complete
response after neoadjuvant chemotherapy in breast cancer patients.
Breast. 44:33–38. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Marín Hernández C, Piñero Madrona A, Gil
Vázquez PJ, Galindo Fernández PJ, Ruiz Merino G, Alonso Romero JL
and Parrilla Paricio P: Usefulness of lymphocyte-to-monocyte,
neutrophil-to-monocyte and neutrophil-to-lymphocyte ratios as
prognostic markers in breast cancer patients treated with
neoadjuvant chemotherapy. Clin Transl Oncol. 20:476–483. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Muñoz-Montaño W, Cabrera-Galeana P,
Alvarado-Miranda A, Villarreal-Garza C, Mohar A, Olvera A,
Bargallo-Rocha E, Lara-Medina F and Arrieta O: Prognostic value of
the pretreatment neutrophil-to-lymphocyte ratio in different
phenotypes of locally advanced breast cancer during neoadjuvant
systemic treatment. Clin Breast Cancer. 20:307–316.e1. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Peng Y, Chen R, Qu F, Ye Y, Fu Y, Tang Z,
Wang Y, Zong B, Yu H, Luo F and Liu S: Low pretreatment
lymphocyte/monocyte ratio is associated with the better efficacy of
neoadjuvant chemotherapy in breast cancer patients. Cancer Biol
Ther. 21:189–196. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bulut G and Ozdemir ZN: Significance of
neutrophil-lymphocyte ratio and Trombocyte-lymphocyte ratio in
predicting complete pathological response in patients with local
advanced breast cancer. Eurasian J Med Invest. 61:78–83. 2022.
|
|
30
|
Cullinane C, Creavin B, O'Leary DP,
O'Sullivan MJ, Kelly L, Redmond HP and Corrigan MA: Can the
neutrophil to lymphocyte ratio predict complete pathologic response
to neoadjuvant breast cancer treatment? A systematic review and
meta-analysis. Clin Breast Cancer. 20:e675–e681. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
McShane LM, Altman DG, Sauerbrei W, Taube
SE, Gion M and Clark GM; Statistics Subcommittee of NCI-EORTC
Working Group on Cancer Diagnostics, : REporting recommendations
for tumor MARKer prognostic studies (REMARK). Breast Cancer Res
Treat. 100:229–235. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sauerbrei W, Taube SE, McShane LM,
Cavenagh MM and Altman DG: Reporting recommendations for tumor
marker prognostic studies (REMARK): An abridged explanation and
elaboration. J Natl Cancer Inst. 110:803–811. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hammond ME, Hayes DF, Wolff AC, Mangu PB
and Temin S: American society of clinical oncology/college of
american pathologists guideline recommendations for
immunohistochemical testing of estrogen and progesterone receptors
in breast cancer. J Oncol Pract. 6:195–197. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wolff AC, Hammond ME, Schwartz JN, Hagerty
KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer
A, et al: American society of clinical oncology/college of American
pathologists guideline recommendations for human epidermal growth
factor receptor 2 testing in breast cancer. J Clin Oncol.
25:118–145. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M,
Fitzgibbons P, et al: Recommendations for human epidermal growth
factor receptor 2 testing in breast cancer: American society of
clinical oncology/college of American pathologists clinical
practice guideline update. J Clin Oncol. 31:3997–4013. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Amin MB, Edge SB, Greene FL, Byrd DR,
Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR,
Sullivan DC, et al: AJCC cancer staging manual. 8th edition.
Springer; 2017
|
|
37
|
Liu X, Qu JK, Zhang J, Yan Y, Zhao XX,
Wang JZ, Qu HY, Liu L, Wang JS and Duan XY: Prognostic role of
pretreatment neutrophil to lymphocyte ratio in breast cancer
patients: A meta-analysis. Medicine (Baltimore). 96:e81012017.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ethier JL, Desautels D, Templeton A, Shah
PS and Amir E: Prognostic role of neutrophil-to-lymphocyte ratio in
breast cancer: A systematic review and meta-analysis. Breast Cancer
Res. 19:22017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Spring LM, Fell G, Arfe A, Sharma C,
Greenup R, Reynolds KL, Smith BL, Alexander B, Moy B, Isakoff SJ,
et al: Pathologic complete response after neoadjuvant chemotherapy
and impact on breast cancer recurrence and survival: A
comprehensive meta-analysis. Clin Cancer Res. 26:2838–2848. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhou Q, Dong J, Sun Q, Lu N, Pan Y and Han
X: Role of neutrophil-to-lymphocyte ratio as a prognostic biomarker
in patients with breast cancer receiving neoadjuvant chemotherapy:
A meta-analysis. BMJ Open. 11:e0479572021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mieog JSD, Van Der Hage JA and Van De
Velde CJH: Preoperative chemotherapy for women with operable breast
cancer. Cochrane Database Syst Rev. 2007:CD0050022007.PubMed/NCBI
|
|
42
|
Denkert C, von Minckwitz G, Darb-Esfahani
S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen
F, Furlanetto J, et al: Tumour-infiltrating lymphocytes and
prognosis in different subtypes of breast cancer: A pooled analysis
of 3771 patients treated with neoadjuvant therapy. Lancet Oncol.
19:40–50. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Schmid P, Cortes J, Dent R, Pusztai L,
McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, et al:
Event-free survival with pembrolizumab in early triple-negative
breast cancer. N Engl J Med. 386:556–567. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
von Au A, Shencoru S, Uhlmann L, Mayer L,
Michel L, Wallwiener M, Hennigs A, Deutsch T, Riedel F, Heil J, et
al: Predictive value of neutrophil-to-lymphocyte-ratio in
neoadjuvant-treated patients with breast cancer. Arch Gynecol
Obstet. 307:1105–1113. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Savioli F, Morrow ES, Dolan RD, Romics L,
Lannigan A, Edwards J and McMillan DC: Prognostic role of
preoperative circulating systemic inflammatory response markers in
primary breast cancer: Meta-analysis. Br J Surg. 109:1206–1215.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mantovani A, Romero P, Palucka AK and
Marincola FM: Tumour immunity: Effector response to tumour and role
of the microenvironment. Lancet. 371:771–783. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Quail DF and Joyce JA: Microenvironmental
regulation of tumor progression and metastasis. Nat Med.
19:1423–1437. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
DeNardo DG, Brennan DJ, Rexhepaj E,
Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD,
Junaid SA, et al: Leukocyte complexity predicts breast cancer
survival and functionally regulates response to chemotherapy.
Cancer Discov. 1:54–67. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Larionova I, Cherdyntseva N, Liu T,
Patysheva M, Rakina M and Kzhyshkowska J: Interaction of
tumor-associated macrophages and cancer chemotherapy.
Oncoimmunology. 8:15960042019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ren Z, Yang J, Liang J, Xu Y, Lu G, Han Y,
Zhu J, Tan H, Xu T and Ren M: Monitoring of postoperative
neutrophil-to-lymphocyte ratio, D-dimer, and CA153 in: Diagnostic
value for recurrent and metastatic breast cancer. Front Surg.
9:9274912023. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lee SK, Choi MY, Bae SY, Lee JH, Lee HC,
Kil WH, Lee JE, Kim SW and Nam SJ: Immediate postoperative
inflammation is an important prognostic factor in breast cancer.
Oncology. 88:337–344. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Moon G, Noh H, Cho IJ, Lee JI and Han A:
Prediction of late recurrence in patients with breast cancer:
Elevated neutrophil to lymphocyte ratio (NLR) at 5 years after
diagnosis and late recurrence. Breast Cancer. 27:54–61. 2020.
View Article : Google Scholar : PubMed/NCBI
|
